MedTrace Logo

A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection

NCT01829971 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 155

Last updated 2016-09-27

No results posted yet for this study

Summary

This is a study to evaluate the safety of MRX34 in patients with primary liver cancer or other selected solid tumors or hematologic malignancies. The drug is given intravenously, for 5 days in a row and then two weeks off.

Conditions

Interventions

DRUG

MRX34

micro RNA therapy

Sponsors & Collaborators

  • Cancer Prevention Research Institute of Texas

    collaborator OTHER

  • Mirna Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • O'Neill VIncent, MD · Mirna Therapeutics

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2017-03-31
Completion
2017-05-31

Countries

  • United States
  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01829971 on ClinicalTrials.gov